Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) – Analysts at B. Riley increased their Q2 2018 EPS estimates for Arrowhead Pharmaceuticals in a research note issued to investors on Monday. B. Riley analyst M. Kumar now anticipates that the biotechnology company will post earnings of ($0.16) per share for the quarter, up from their prior forecast of ($0.23). B. Riley currently has a “Neutral” rating and a $4.00 target price on the stock. B. Riley also issued estimates for Arrowhead Pharmaceuticals’ Q3 2018 earnings at ($0.16) EPS, Q4 2018 earnings at ($0.16) EPS, FY2018 earnings at ($0.62) EPS, FY2019 earnings at ($0.44) EPS, FY2020 earnings at ($0.48) EPS, FY2021 earnings at ($0.70) EPS and FY2022 earnings at ($0.70) EPS.
Other equities research analysts have also issued reports about the company. BidaskClub lowered Arrowhead Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Wednesday. ValuEngine upgraded Arrowhead Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Friday, February 2nd. Piper Jaffray Companies upgraded Arrowhead Pharmaceuticals from a “neutral” rating to an “overweight” rating and set a $5.50 price objective for the company in a research note on Monday, November 27th. Chardan Capital restated a “neutral” rating on shares of Arrowhead Pharmaceuticals in a research note on Tuesday, January 16th. Finally, Cantor Fitzgerald set a $2.00 price objective on Arrowhead Pharmaceuticals and gave the stock a “hold” rating in a research note on Tuesday, December 12th. Five analysts have rated the stock with a hold rating and three have given a buy rating to the stock. Arrowhead Pharmaceuticals presently has an average rating of “Hold” and an average price target of $4.13.
Arrowhead Pharmaceuticals (NASDAQ:ARWR) last posted its quarterly earnings data on Tuesday, December 12th. The biotechnology company reported ($0.14) EPS for the quarter, missing the consensus estimate of ($0.12) by ($0.02). The company had revenue of $8.71 million during the quarter, compared to analysts’ expectations of $7.32 million. Arrowhead Pharmaceuticals had a negative return on equity of 40.38% and a negative net margin of 116.17%.
A number of institutional investors have recently modified their holdings of ARWR. Virtu KCG Holdings LLC boosted its holdings in Arrowhead Pharmaceuticals by 115.6% in the 2nd quarter. Virtu KCG Holdings LLC now owns 99,267 shares of the biotechnology company’s stock worth $161,000 after buying an additional 53,215 shares during the period. Dimensional Fund Advisors LP boosted its holdings in Arrowhead Pharmaceuticals by 252.2% in the 3rd quarter. Dimensional Fund Advisors LP now owns 44,358 shares of the biotechnology company’s stock worth $192,000 after buying an additional 31,765 shares during the period. Wells Fargo & Company MN boosted its holdings in shares of Arrowhead Pharmaceuticals by 237.3% during the 4th quarter. Wells Fargo & Company MN now owns 69,997 shares of the biotechnology company’s stock valued at $257,000 after purchasing an additional 49,246 shares during the last quarter. Acadian Asset Management LLC boosted its holdings in shares of Arrowhead Pharmaceuticals by 1,177.7% during the 4th quarter. Acadian Asset Management LLC now owns 71,664 shares of the biotechnology company’s stock valued at $264,000 after purchasing an additional 66,055 shares during the last quarter. Finally, Alps Advisors Inc. bought a new position in shares of Arrowhead Pharmaceuticals during the 4th quarter valued at about $305,000. 20.48% of the stock is owned by institutional investors.
In related news, COO Bruce D. Given sold 20,000 shares of the company’s stock in a transaction on Monday, January 1st. The shares were sold at an average price of $3.69, for a total value of $73,800.00. Following the completion of the transaction, the chief operating officer now owns 948,356 shares of the company’s stock, valued at approximately $3,499,433.64. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Corporate insiders own 4.60% of the company’s stock.
WARNING: This news story was first reported by American Banking News and is the property of of American Banking News. If you are reading this news story on another site, it was illegally copied and reposted in violation of US and international trademark & copyright laws. The correct version of this news story can be viewed at https://www.americanbankingnews.com/2018/02/14/q2-2018-eps-estimates-for-arrowhead-pharmaceuticals-inc-arwr-lifted-by-analyst.html.
Arrowhead Pharmaceuticals Company Profile
Arrowhead Pharmaceuticals, Inc, formerly Arrowhead Research Corporation, develops medicines that treat intractable diseases by silencing the genes that cause them. Using a portfolio of ribonucleic acid (RNA) chemistries and modes of delivery, the Company’s therapies trigger the RNA interference mechanism to induce knockdown of target genes.
Receive News & Ratings for Arrowhead Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arrowhead Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.